AstraZeneca
Tracked across 69 events · 3276 articles · First seen Mar 09, 2018 · Last active Aug 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: AstraZeneca expands its lung cancer portfolio with a novel oral EGFR inhibitor, complementing existing drugs like Tagrisso. The deal involves a $600M upfront payment and potential milestones, but does not affect 2026 guidance.
Jul 14, 2026 · 8 articles
Business
Impact: AstraZeneca is the initiator of the merger talks, seeking to expand its US presence. Its shares fell over 7% on the news, reflecting investor skepticism about the deal's value and execution risk.
Aug 02, 2026 · 60 articles
Business
AstraZeneca announced on August 17, 2026, that it is discontinuing the Phase III EVOLVE-Lung02 trial of volrustomig plus chemotherapy in patients with metastatic non-small cell lung cancer (mNSCLC). The decision followed a recommendation from an…
Impact: AstraZeneca is the central company, facing another pipeline setback with the discontinuation of the volrustomig trial. Despite this, it reported positive results from other trials and reaffirmed its 2030 revenue target, with shares rising slightly.
Aug 17, 2026 · 20 articles
Business
On 19 August 2026, Danone — Alpro, in collaboration with AstraZeneca Malaysia, announced the launch of the nationwide #AreYourKidneysOK+? campaign in Malaysia. The initiative aims to raise awareness of hyperkalemia and promote early detection across…
Impact: AstraZeneca Malaysia collaborates with Danone — Alpro, reinforcing its commitment to addressing chronic kidney disease and hyperkalemia. The campaign may support its market position and brand image.
Aug 19, 2026 · 6 articles
Business
Impact: AstraZeneca expands its oncology footprint in India, enhancing its brand and potential revenue from genomic diagnostics and AI solutions.
Jul 28, 2026 · 8 articles
Regulatory
Impact: AstraZeneca, as HUTCHMED's partner, jointly developed and commercializes ORPATHYS (savolitinib). The approval in China for gastric cancer expands its market reach and reinforces its precision medicine strategy.
Jul 02, 2026 · 6 articles
Business
Impact: AstraZeneca celebrated its February transfer to the New York Stock Exchange, which was the largest transfer by market capitalization in the exchange's history, indicating a positive move for the company's market presence.
Jun 05, 2026 · 10 articles
Business
Impact: AstraZeneca's stock fell 5.7% after the trial failure; it faces investor investigations and potential legal liability.
Jul 09, 2026 · 46 articles
Business
Impact: AstraZeneca gains access to decentralized companion diagnostics for its oncology therapies, which could improve patient access and therapy adoption, supporting its drug sales and pipeline success.
Aug 04, 2026 · 8 articles
Tech
Impact: AstraZeneca is collaborating on the DURIPANC study, providing its drug Imfinzi, and stands to benefit from the success of the combination therapy.
Jun 01, 2026 · 10 articles
Business
Impact: AstraZeneca's cliramitug is the subject of the royalty acquisition; the deal does not directly affect AstraZeneca's financials but underscores the drug's commercial potential.
Jul 22, 2026 · 7 articles
Domestic
Impact: As a major pharmaceutical company, AstraZeneca can now sponsor researchers through the Global Talent visa, potentially enhancing its R&D capabilities.
Aug 05, 2026 · 6 articles
International
Impact: AstraZeneca announced a significant investment of $15 billion in China through 2030 to expand its medicines manufacturing and research, demonstrating confidence in the Chinese market.
Jan 30, 2026 · 9 articles
International
Impact: AstraZeneca featured an AI-powered drug discovery platform, advancing precision diagnostics and treatment.
Jun 15, 2026 · 87 articles
Business
SK Biopharmaceuticals, a leading innovation-driven pharmaceutical company in China, announced the launch of its new global brand, SBP Group, during its interim results meeting on August 19, 2026. The brand name stands for Science, Breakthroughs…
Impact: AstraZeneca licensed TQC3721, an inhaled PDE3/4 inhibitor for COPD, from Sino Biopharmaceutical in a deal valued up to US$1.9 billion. This strengthens AstraZeneca's respiratory pipeline and aligns with its focus on chronic diseases.
Jul 20, 2026 · 6 articles
Tech
Impact: AstraZeneca has partnered with Quell Therapeutics to develop therapies for inflammatory bowel disease, indicating its interest in the field of immune tolerance.
Oct 06, 2025 · 6 articles
Business
Impact: AstraZeneca is a recipient of the 2026 Visionary Growth Leadership Best Practices Recognition, which could positively influence its brand image and investor perception.
Jun 15, 2026 · 6 articles
Regulatory
Impact: AstraZeneca benefits from the expanded label of the VENTANA MMR RxDx Panel as it identifies patients eligible for its Durvalumab and Olaparib therapies, potentially increasing the drugs' market reach.
Jun 11, 2026 · 6 articles
Business
Impact: Maria G. Belvisi previously served as Senior Vice President, Research & Development, Respiratory & Immunology at AstraZeneca, where she led the development of tozorakimab.
Apr 10, 2026 · 6 articles
Regulatory
Impact: AstraZeneca's Lynparza faces generic competition if the tentative approval leads to final launch. The ongoing Paragraph IV litigation may delay market entry.
Jul 19, 2026 · 6 articles
Business
Impact: AstraZeneca participated in the symposium, contributing to discussions on decarbonization and green chemistry.
Jul 20, 2026 · 6 articles
Domestic
Impact: AstraZeneca, among other pharmaceutical companies, had previously announced investments in U.S. production due to the threat of tariffs, but the new, higher tariffs introduce further uncertainty.
Sep 26, 2025 · 7 articles
International
Impact: AstraZeneca executives participated in the Qingdao International City Partner Dialogue, engaging in discussions on sci-tech innovation and cooperation.
Jun 11, 2026 · 9 articles
Accidents
Impact: AstraZeneca was involved in the development of the COVID-19 vaccine platform that is now being considered for a Bundibugyo ebolavirus vaccine, showcasing its role in vaccine innovation.
May 18, 2026 · 505 articles
Tech
Impact: AstraZeneca>>> developed Tagrisso, a tyrosine kinase inhibitor used to treat Michelle Vacca>>>'s EGFR-mutated lung cancer.
Jun 03, 2026 · 6 articles
Tech
Impact: AstraZeneca>>> is among global drugmakers deploying AI to identify trial participants more quickly and cut time for drug safety reports, potentially saving millions of dollars.
May 28, 2026 · 6 articles
Regulatory
On August 5, 2026, the U.S. United States — Food and Drug Administration (FDA) approved Moderna's mFLUSIVA (mRNA-1010), the first mRNA-based seasonal influenza vaccine, for adults aged 50 and older. The approval covers traditional approval…
Impact: AstraZeneca's flu vaccine portfolio could be affected by the entry of mFLUSIVA.
Aug 05, 2026 · 105 articles
Business
A wave of strong corporate earnings, particularly from AI-related companies, drove major U.S. stock indexes to record highs in early August 2026. Microsoft, Amazon (company), Palantir, and Caterpillar reported better-than-expected results, easing investor concerns about…
Impact: Investors punished the stock over merger talks with Bristol Myers Squibb.
Jul 14, 2026 · 280 articles
Accidents
The Democratic Republic of the Congo is experiencing its largest and fastest-growing Ebola outbreak on record, caused by the rare Bundibugyo virus for which there are no approved vaccines or treatments. The outbreak, declared on…
Impact: Its COVID-19 vaccine technology is used in the Oxford candidate, but AstraZeneca itself is not directly involved in the Ebola response.
Mar 09, 2018 · 543 articles
Accidents
The Democratic Republic of the Congo is experiencing its deadliest Ebola outbreak on record, caused by the rare Bundibugyo ebolavirus. As of August 19, 2026, the outbreak has surpassed 5,000 confirmed cases and over 2,300…
Impact: Technology from its COVID-19 vaccine is used in the Oxford Ebola vaccine, indirectly involved.
Aug 01, 2026 · 295 articles
+ 39 more events
View on Dashboard
100
AstraZeneca discontinued trialAstraZeneca discontinues...
90
SK Biopharmaceuticals licensed TQC3721 to AstraZeneca AstraZenecaSino Biopharmaceutical...
80
AstraZeneca explored merger Bristol Myers SquibbAI earnings drive record...
80
AstraZeneca collaborated with Danone — AlproAlpro Group and...
70
Bristol Myers Squibb held merger talks AstraZenecaAI earnings drive record...
65
AstraZeneca developed TagrissoAstraZeneca discontinues...
50
AstraZeneca saw stock dropAstraZeneca discontinues...
40
AstraZeneca reaffirmed revenue targetAstraZeneca discontinues...
30
AstraZeneca gained 1.3%AstraZeneca discontinues...
30
AstraZeneca continued other trialsAstraZeneca discontinues...
+ 50 more relationships
View on Dashboard
ERGEN INTELLIGENCE
Track AstraZeneca live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard